CODA Biotherapeutics, Inc.

CODA Biotherapeutics, Inc. focuses on developing innovative biotherapeutics to address neurological disorders, primarily leveraging advanced gene therapy techniques to improve patient outcomes in areas such as neuropathic pain and focal epilepsy. Founded in 2014 and headquartered in South San Francisco, US, CODA Biotherapeutics, Inc. specializes in the development of biotherapeutics targeting neurological disorders.

The company was founded by Mitchell Finer and has raised a total of USD 15. 00 mn through various funding rounds, with the most recent round being a Grant amounting to USD 0. 67 mn from investors including Small Business Innovation Research and The National Institutes of Health on December 2, 2021. CODA Biotherapeutics is dedicated to developing cutting-edge biotherapeutic solutions aimed at treating neurological conditions such as neuropathic pain and focal epilepsy.

By employing advanced gene therapy technologies, the company seeks to create effective treatment options that enhance patient quality of life. CODA Biotherapeutics generates revenue through grants and funding opportunities aimed at supporting its research and development initiatives. The company has raised a total of USD 15. 00 mn from various funding rounds, ensuring the continuation of its innovative projects.

Moving forward, CODA Biotherapeutics plans to utilize the recent funding from its December 2021 round to advance its research platform, particularly focusing on treatments for neuropathic pain and focal epilepsy. The company aims to expand its product offerings and enhance its therapeutic pipeline, while exploring opportunities for growth in the neurological therapeutics market globally.